| Disease | IN A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THE ENCEPHALOTROPIC AND PSYCHOTROPIC EFFECTS OF KAVAIN, 15 NORMAL VOLUNTEERS RECEIVED RANDOMIZED IN WEEKLY INTERVALS SINGLE ORAL DOSES OF PLACEBO, 200 MG, 400 MG, AND 600 MG KAVAIN AS WELL AS 30 MG
CLOBAZAM AS REFERENCE COMPOUND. BRAIN MAPS OF DRUG INDUCED PHARMACO-EEG CHANGES DEMONSTRATED THAT KAVAIN EXERTED A SIGNIFICANT ACTION ON THE HUMAN BRAIN FUNCTION. THESE FINDINGS ARE INDICATIVE OF A SEDATIVE EFFECT. KAVAIN IMPROVED THE NOOPSYCHE
COMPARED WITH PLACEBO IN ALL 3 DOSES AS THERE WAS A SIGNIFICANT IMPROVEMENT IN INTELLECTUAL PERFORMANCE, ATTENTION, CONCENTRATION, REACTION TIME AND MOTOR SPEED. IN REGARD TO THYMOPSYCHIC VARIABLES SUCH AS DRIVE, WAKEFULNESS, AFFECTIVITY, MOOD,
WELL-BEING, 200 MG KAVAIN PRODUCED AN IMPROVEMENT AS COMPARED WITH PLACEBO WHILE 600 MG KAVAIN PRODUCED SEDATION AS DID 30 MG CLOBAZAM. |